EFNB1 Acts as a Novel Prognosis Marker in Glioblastoma through Bioinformatics Methods and Experimental Validation

Figure 8

Prognostic performance of the risk signature. (a, b) Distribution of risk score in the TCGA and CGGA cohorts. (c, d) Survival outcomes of patients in the TCGA and CGGA data sets. (e, f) Heatmap displaying signature genes in the two risk groups. (g, h) Kaplan–Meier analysis of patients in the two risk groups. (i), (j) ROC curves at 1, 3, and 5 years in the TCGA and CGGA cohorts.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)